EP 1042498 A1 20001011 - A METHOD OF FINDING AGONIST AND ANTAGONIST TO HUMAN 11CB SPLICE VARIANT
Title (en)
A METHOD OF FINDING AGONIST AND ANTAGONIST TO HUMAN 11CB SPLICE VARIANT
Title (de)
METHODE ZUM AUFFINDEN VON EINEM AGONISTEN UND EINEM ANTAGONISTEN DER MENSCHLICHEN 11CB SPLEISS-VARIANTE
Title (fr)
PROCEDE DE RECHERCHE D'UN AGONISTE OU D'UN ANTAGONISTE DU VARIANT D'EPISSAGE DE 11 CB HUMAIN
Publication
Application
Priority
- US 9825497 W 19981202
- US 98428897 A 19971203
- US 7374798 P 19980205
- US 6050498 A 19980415
Abstract (en)
[origin: WO9928492A1] Human 11cb splice variant polypeptides and DNA (RNA) encoding such an 11cb splice variant and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such an 11cb splice variant for the treatment of to treat infections, such as bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; feeding and drinking abnormalities, such as anorexia and bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation, and dyskinesias, such as Huntington's disease or Gilles de la Tourett's syndrome; among others. Antagonists against such an 11cb splice variant and their use as a therapeutic to treat infections, such as bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; feeding and drinking abnormalities, such as anorexia and bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation, and dyskinesias, such as Huntington's disease or Gilles de la Tourett's syndrome; among others, are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the 11cb splice variant and for detecting altered levels of the polypeptide in a host.
IPC 1-7
IPC 8 full level
C12N 15/09 (2006.01); A61K 38/00 (2006.01); A61K 45/00 (2006.01); A61P 9/00 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01); C07H 21/02 (2006.01); C07K 14/47 (2006.01); C07K 14/72 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12P 21/02 (2006.01)
CPC (source: EP)
A61P 9/00 (2017.12); A61P 25/00 (2017.12); A61P 29/00 (2017.12); A61P 31/00 (2017.12); A61P 35/00 (2017.12); C07K 14/721 (2013.01); A61K 38/00 (2013.01)
Designated contracting state (EPC)
BE CH DE DK FR GB IT LI NL
DOCDB simple family (publication)
WO 9928492 A1 19990610; EP 1042498 A1 20001011; EP 1042498 A4 20030507; JP 2001525178 A 20011211
DOCDB simple family (application)
US 9825497 W 19981202; EP 98962869 A 19981202; JP 2000523368 A 19981202